FDA Rare Disease Innovation Hub
FDA created the Rare Disease Innovation Hub (the Hub) to serve as a point of collaboration and connectivity between CBER and CDER.
Related Articles
Addressing Health Care’s Administrative Cost Crisis
This Viewpoint argues that standardizing and streamlining administrative tasks could decrease health care costs and have a direct positive effect on patients and clinicians.
DEA unveils telehealth rules for Adderall, buprenorphine, other controlled medications
The DEA’s long-awaited rule would allow providers on a new registry prescribe controlled medications. But there are restrictions.
Trump’s last-minute plan to save TikTok from nationwide ban revealed
President-elect Donald Trump may issue an executive order that would suspend the TikTok ban scheduled to go into effect on Sunday.
Could Timelier Referrals for VADs Improve Outcomes in Children With CHD?
When undergoing ventricular assist device (VAD) implantation, children with congenital heart disease are more likely to experience adverse outcomes, highlights the need for a timely…
From LDL-C to Lp(a): A Multispecialty Approach to Reducing the Rising Tide of Cardiovascular Disease
Panelists discuss how comprehensive cardiovascular disease management requires integrating screening protocols, risk assessment, and targeted interventions across the lifespan, from pediatric lipid testing through adult…
Carbonic anhydrase inhibitors and high altitude illnesses – PubMed
Carbonic anhydrase (CA) inhibitors, particularly acetazolamide, have been used at high altitude for decades to prevent or reduce acute mountain sickness (AMS), a syndrome of…
Los Angles Needs to Fireproof Communities, Not Just Houses
After the devastation of the Los Angeles fires, officials are ready to rebuild. But defending against future fires requires thinking about more than buildings.
Signs of a Stroke: Act Quickly With BE FAST
Here’s a scary fact: Only an estimated 36% of people in the U.S. know even one of the signs of a stroke. A neurologist explains…
Factors Associated With Enrollment to a Decentralized Study
To assess whether the mode and formatting of invitations affect enrollment in a large, decentralized study.
Demoting BMI, a new food label from the FDA, and risks of even moderate drinking
An international group of experts proposes two new categories of disease: preclinical and clinical obesity and the FDA introduces a new food label.